XLXing Li

Xing Li

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Xing Li has a total of 5 co-authors. Here are the top co-authors by number of shared publications:

  • Junming He

    Department of Hepatobiliary Surgery, The Second AffiliatedHospital of Guangzhou University of Chinese Medicine, Guangzhou, 510120, China

    1 shared publication
  • Lixing Cao

    Department of Perioperative Research Centre of Chinese Medicine, The Second Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, 510120, China

    1 shared publication
  • Qicheng Chen

    Department of Perioperative Research Centre of Chinese Medicine, The Second Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, 510120, China

    1 shared publication
  • Zhi Jiang

    Department of Perioperative Research Centre of Chinese Medicine, The Second Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, 510120, China

    1 shared publication
  • Zhiqiang Chen

    Hebei University of Chinese Medicine

    1 shared publication

Latest Publications

  • Wuda Granule Modulates miR-635-3p Expression to Downregulate CCL11 and Restrain Colorectal Cancer Proliferation

    by Zhi Jiang, Xing Li, Qicheng Chen, Zhiqiang Chen, Junming He, Lixing Cao

    Introduction: Colorectal cancer (CRC) is a leading cause of cancer-related deaths globally, with a rising incidence in developing regions. The Traditional Chinese Medicine formulation Wuda granule (WDG) shows potential in treating gastrointestinal motility disorders, but its role and molecular mechanisms in CRC remain unclear. Methods: miRNA microarray and quantitative real-time PCR (qRT-PCR) analyses were used to assess miR-656-3p expression in smooth muscle cells from five CRC patients and colorectal cancer cell lines following WDG treatment. Functional assays, including colony formation and CCK-8 proliferation tests, evaluated the effects of miR-656-3p overexpression on CRC cell proliferation. Bioinformatics prediction, gene expression analysis, Western blotting, immunofluorescence, and dual- luciferase reporter assays were conducted to identify and validate CCL11 as a direct target of miR-656-3p. The impact of WDG treatment on CCL11 expression was examined with and without miR-656-3p inhibition. Additionally, the role of CCL11 overexpression in reversing WDG-induced effects was investigated. Results: WDG treatment significantly upregulated miR-656-3p expression in smooth muscle cells of CRC patients and colorectal cancer cell lines. Overexpression of miR-656-3p markedly inhibited CRC cell proliferation. CCL11 was identified as a direct target of miR-656-3p, with WDG treatment reducing CCL11 expression at both mRNA and protein levels. Inhibition of miR-656-3p reversed this effect, while overexpression of CCL11 rescued the proliferative capacity of CRC cells suppressed by WDG treatment. Discussion: Our findings identified miR-656-3p as a tumor suppressor in colorectal cancer through its direct targeting of CCL11. We further demonstrated that Wuda granule exerts anti-tumor effects by upregulating miR-656-3p, revealing a novel therapeutic mechanism. This study provides new insights into miRNA-based therapies for CRC, highlighting the clinical potential of targeting the miR656-3p/CCL11 axis. Conclusion: Wuda granule inhibits colorectal cancer growth through a miR-656-3p-mediated suppression of CCL11, validating the miR-656-3p/CCL11 axis as a potential therapeutic target for CRC management.